Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b

An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin

(2012) C. Kondo et al.   JOURNAL OF VIRAL HEPATITIS

Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin

(2011) Masashi Namikawa et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin

(2011) Yuko Inoue et al.   JOURNAL OF MEDICAL VIROLOGY

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

(2011) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identifying HCV genotype 1 patients at risk of relapse

(2010) Marc Deschênes et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Statin Therapy Improves Sustained Virologic Response Among Diabetic Patients With Chronic Hepatitis C

(2010) Gowtham A. Rao et al.   GASTROENTEROLOGY

Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors

(2010) Masayuki Kurosaki et al.   JOURNAL OF HEPATOLOGY

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

(2010) Min Gao et al.   NATURE

Peginterferon Alfa-2a/Ribavirin for 48 or 72 Weeks in Hepatitis C Genotypes 1 and 4 Patients With Slow Virologic Response

(2009) Peter Ferenci et al.   GASTROENTEROLOGY

Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients

(2009) Henk W. Reesink et al.   GASTROENTEROLOGY

An Open Pilot Study Exploring the Efficacy of Fluvastatin, Pegylated Interferon and Ribavirin in Patients with Hepatitis C Virus Genotype 1b in High Viral Loads

(2009) Hitomi Sezaki et al.   INTERVIROLOGY

Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin

(2009) N. Hiramatsu et al.   JOURNAL OF VIRAL HEPATITIS

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

(2009) Dongliang Ge et al.   NATURE

IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy

(2009) Vijayaprakash Suppiah et al.   NATURE GENETICS

Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C

(2009) Yasuhito Tanaka et al.   NATURE GENETICS

Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection

(2009) Christophe Hézode et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

(2009) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

(2009) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fluvastatin Inhibits Hepatitis C Replication in Humans

(2008) Ted Bader et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin

(2008) Paul J. Pockros et al.   HEPATOLOGY

HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity In Vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus

(2008) Norman M. Kneteman et al.   HEPATOLOGY

Robust antiviral activity of R1626, a novel nucleoside analog: A randomized, placebo-controlled study in patients with chronic hepatitis C

(2008) Stuart K. Roberts et al.   HEPATOLOGY